GNOM News and Press, Global X Genomics & Biotechnology ETF From 02/02/22

The goal of the DDM is to quickly and easily utilize available resources of an asset to understand what the intrinsic value of that asset is based on certain market and company expectations. If the required return component of the equation rises without expectations of higher company ...

The anticipated end of the pandemic causes volatility because a transition phase will be priced as a new rotation from, for example, defensive staples to healthcare. Healthcare ETFs can add a defense to a portfolio that is overweight cyclicals, energy, and financials. US Airlines ...

Agriculture really hasn’t changed in 12,000 years. Part of the reason for that is we just didn’t have enough technology. There are different types of technologies, some within the realm of artificial intelligence but certainly also in robotics, that can now take bits of ...

At the end of 2019, had we been told that a two-year pandemic was about to begin, we would have found it impossible to predict the set of returns that followed in subsequent years. Historically, “tightening,” or “over-tightening,” policy was about corrallin...

Aeta: We know the transmissibility is higher for the omicron variant and will impact vaccine efficacy, but anecdotal hospital reports suggest that it milder. Aeta: Health care is having a solid year but is still lagging the market, as cyclicals are outperforming due to the strong econ...

While inflation was at first believed to be transitory, it is now beginning to look persistent. Biotech stocks are close to 6.5% of the Russell 2000 Value Index benchmark, and only a few have earnings and positive cash flows. We also think the outlook is rosy for small-cap value i...

With each new outbreak and variant, comes new fears, government lockdowns and hopes for recovery through science and medicine in the form of effective vaccines. Until recently, investor mindsets had shifted to a “living with COVID-19” mentality, supported by abundant sti...

The latest IHS Markit US Sector PMI revealed that six of the seven broad sectors tracked by the surveys reported higher output in November. Despite some of the supply chain problems having eased in November, the extent to which production growth had been constrained is consistent with...

The biotechnology sector largely underperformed the broader market this year, particularly small- to mid-cap biotech indexes whose constituents tend to experience more volatility. Contributing factors to the market decline include fears of increased regulation and oversight of M&A...

The revolutionary technology of synthetic biology is poised to make a profound impact on the way a vast array of products are manufactured, from lab-grown meat to cosmetics to biodegradable packaging. Like the internet revolution, companies that enable or effectively harness synthetic...